W L Gore & Associates (Gore) announced today the first clinical cases in Australia involving their new revolutionary instrument, the DrySeal Sheath. The sheath aids in minimally invasive treatment of patients with abdominal and thoracic aortic aneurysms (AAA and TAA) utilizing the Gore Excluder AAA Endoprosthesis and Gore Tag Thoracic Endoprosthesis respectively.
The first successful procedures were performed by Thomas Daly at Westmead Hospital, Alan Bray at Newcastle Private (both in New South Wales), and Michael Denton from Epworth Private Hospital, Victoria. According to Dr. Daly, who performed the first clinical case in Australia, “the haemostasis achieved with the Gore DrySeal Sheath is unsurpassed by any other large diameter commercial sheath. Its versatility reduces patient blood loss while not compromising accessibility.”
The Gore DrySeal Sheath, comprises a hemostatic valve attached to the introducer sheath, pressurized to create a seal, thereby minimising blood loss and accommodating multiple wires and catheters simultaneously. The valve consists of a silicone outer tube and an inner film tube that create an effective hemostatic seal that easily adapts to the profiles of the inserted devices. The Gore DrySeal Sheath is available in profiles from 12 to 26 Fr and has a working length of 28 centimetres.
The company’s business leader David Abeyta added, “The Gore DrySeal Sheath is the newest addition to Gore’s world-class portfolio and is further evidence of Gore’s commitment to the development of innovative solutions to address unmet clinical needs in the Australian endovascular market.”
